Ad-hoc | 27 October 2005 14:17

STRATEC matches entire 2004 earnings after only nine months

Ad hoc announcement §15 WpHG Results STRATEC matches entire 2004 earnings after only nine months Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC matches entire 2004 earnings after only nine months Birkenfeld, October 27, 2005 The Board of Management of STRATEC Biomedical Systems AG, listed in the German Prime Standard and in Gate-M, hereby announces the results for the first nine months of FY 2005, pursuant to Section 15 of the German Securities Trading Law (WpHG). STRATEC increased its earnings to EUR 2.894m (2004: EUR 1.910m). This results in earnings per share (EPS) amounting to EUR 0.87 (2004: EUR 0.58). The diluted earnings per share are EUR 0.85 (2004: EUR 0.57). This calculation takes account of the dilution resulting from the capital increase undertaken in September 2005. Sales increased by 21.1% to EUR 33.945m (2004: EUR 28.022m). The overall performance improved by 21.0% to EUR 35.582m (2004: EUR 29.397m). STRATEC had a total of 189 employees as of September 30, 2005 (2004: 172). Overview of key figures pursuant to IFRS (International Financial Reporting Standards): Key figures in 000s 01.01.-09.30.2005 01.01.-09.30.2004 Change Sales 33,945 28,022 +21.1% Overall performance 35,582 29,397 +21.0% EBITDA 5,330 3,955 +34.8% EBIT 4,602 3,243 +41.9% EBT 4,424 3,045 +45.3% Net income for the period 2,894 1,910 +51.5% STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland ISIN: DE0007289001 WKN: 728900 Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart (Gate-M); Freiverkehr in Berlin-Bremen, Düsseldorf und München End of ad hoc announcement (c)DGAP 27.10.2005 Issuer’s information/explanatory remarks concerning this ad hoc announcement: The listed holding company “STRATEC Biomedical Systems AG” and its wholly- owned subsidiary “Robion AG” were fully consolidated for the first time as of September 30, 2005. Consolidated financial statements based on International Financial Reporting Standards (IFRS) will be compiled for this reporting entity for the first time as of December 31, 2005. In view of its insignificant material relevance, the slightly positive earnings reported by the wholly-owned subsidiary “STRATEC NewGen GmbH” is not be consolidated. Although none of our partners has yet newly launched any analyzer systems developed by STRATEC onto the market in the FY 2005, the company has achieved a significant increase in its sales. Earnings in turn have risen even more rapidly as on account of the resultant benefits of scale and degression effects. The extensive interim report can be downloaded from our homepage from around 3 p.m. on November 9, 2005. About STRATEC STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. The STRATEC group comprises the listed holding company “STRATEC Biomedical Systems AG” as well as the wholly-owned subsidiaries “STRATEC NewGen GmbH” and “Robion AG”. Further information can be obtained from: STRATEC Biomedical Systems AG Investor Relations André Loy Gewerbestrasse 37 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de End of message (c)DGAP 271417 Okt 05